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because of concerns over the durability of the reconstruction
and perceived complications such as infection.12-17 In this
study, we reviewed our experience with the use of prosthetic
conduits in renal artery reconstruction.
METHODS
We reviewed the records of all patients undergoing
renal artery reconstructions between 1987 and 1999. We
further identified those patients undergoing renal artery
bypass grafting with a prosthetic conduit. These data were
prospectively collected in a computerized vascular registry
and corroborated with review of patient charts.
Preoperatively, patients underwent biplanar arteriogra-
phy. In patients with a suspected aortic aneurysm, a com-
puted tomography scan was performed. Indications for
renal artery reconstructions included renal insufficiency
(serum creatinine levels > 1.5 mg/dL) with a salvageable
kidney, presumed renovascular hypertension, severe (>
70%) asymptomatic stenosis in a setting of abdominal aor-
tic aneurysm or symptomatic aortoiliac occlusive disease,
and renal artery anatomy that necessitated reimplantation
or revascularization in the setting of other disease processes
(ie, graft infection, trauma, or renal artery aneurysm).
Patients with creatinine levels of 1.5 mg/dL or less or who
were taking less than three antihypertensive medications
were considered symptom free. Patients with primary reno-
vascular hypertension were evaluated with biplanar contrast
angiography, magnetic resonance angiography with or
without gadolinium, or carbon dioxide angiography. In
addition, many were also evaluated with selective renal vein
renin values or captopril-stimulated scintigraphy. The pre-
operative cardiac evaluation included a review of each
patient’s medical history and each patient undergoing a
Surgical reconstruction of stenotic renal arteries has
been proven effective in the treatment of renovascular
hypertension, preservation of renal mass, and improve-
ment of function in patients with renal insufficiency.1-4
The reconstruction of asymptomatic, severe renal artery
stenosis (RAS) is somewhat more controversial but has
been advocated in a good-risk patient when the primary
indication for surgery is aortic replacement for aneurysm
or occlusive disease.5,6 In an earlier study, we performed
concomitant treatment of aortic and renal disease with
acceptable mortality and morbidity rates.7 Justification of
such procedures has been provided by natural history
studies in which significant progression of RAS to occlu-
sion with subsequent loss of function has been docu-
mented.8-10
In the aforementioned clinical studies, many authors
have preferentially used autogenous forms of renal artery
reconstruction with saphenous vein bypass graft, arterial
autografts, or transaortic endarterectomy.1,11 These recon-
structions have been performed either primarily or in com-
bination with an aortic reconstruction. The use of prosthetic
grafts in this setting has been somewhat controversial
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Is prosthetic renal artery reconstruction a durable
procedure? An analysis of 489 bypass grafts
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Objective: Renal artery stenosis has been classically addressed with saphenous vein bypass graft or transaortic endarterec-
tomy performed either primarily or in combination with an aortic procedure. In this series, we report the outcome of
our 12-year experience with renal artery reconstruction using prosthetic conduit.
Methods: Patients undergoing renal artery bypass grafting from 1987 to 1999 were identified. Demographics, indica-
tions, concurrent operations, complications, and patency were analyzed. Patients underwent postoperative duplex scan
with subsequent ultrasound scans at 6-month intervals. 
Results: There were 489 procedures performed in 414 patients with indications: high-grade renal artery stenosis in
combination with abdominal aortic aneurysm repair or symptomatic aortoiliac occlusive disease (309 [63%]), renovas-
cular hypertension (118 [24%]), and renal salvage (20 [4%]). Indications for the remainder included trauma, renal
artery aneurysm, or an infected aortic graft. Inflow was aorta or aortic graft in 95% of patients with the remainder
taken from the iliac or visceral vessels. The retroperitoneal approach was used in 97.8%. Nonfatal complications
occurred in 11.4% with a 1.4% early and 4.8% late occlusion rate. Renal function worsened in 3.1% of all patients.
Secondary patency at 1 and 5 years was 98% and 96%, respectively.
Conclusion: Renal artery reconstruction with prosthetic conduit has an acceptable and durable result whether used for pri-
mary renal artery reconstruction or concomitant reconstruction with aortic procedures. (J Vasc Surg 2001;34:127-32.)
physical examination and an electrocardiogram. A thallium
dipyridamole stress test and cardiac catheterizations were
performed when indicated.
In the selective renal vein renin studies, catheters were
placed via femoral venous puncture at the orifices of the
right and left renal veins for renin sampling. In addition, a
sample was taken from the infrarenal inferior vena cava.
Tests results were read as positive for the particular renal
artery if the ratio of the corresponding renal vein to inferior
vena cava renin exceeded 1.5. Captopril-stimulated renal
scintigraphy studies were performed as follows: patients
were hydrated intravenously over 1 hour with 1000 mL of
0.45% sodium chloride injection. Angiotensin-converting
enzyme (ACE) inhibitors were ideally withheld for 7 days
before the study, and long-term diuretic administration was
stopped several days before the study, if possible. Captopril
(50 mg) was given orally 60 minutes before tracer injection.
Renal flow scans were performed with Tc 99m MAG3
(technetium Tc 99m mertriatide). If results of the ACE
inhibitor renal study were abnormal, a baseline Tc 99m
MAG3 renal study was performed later, when the patient
had not been taking ACE inhibitors for at least 7 days. The
results of tests were read as positive if there was an aug-
mentation in renal perfusion deficits after captopril infusion.
All patients were administered general anesthesia with
full invasive monitoring; 25 g of mannitol was given intra-
venously before the incision to promote diuresis. A “renal”
dose of dopamine (2 mg/kg) was started after induction,
and heparin (30 U/kg) was given intravenously before
arterial cross-clamping. Reconstructions were preferably
performed through the retroperitoneal approach, although
selected procedures were performed by a transabdominal
approach. Reconstructions of the renal artery with pros-
thetic conduits involved polytetrafluoroethylene (PTFE) in
all cases.
The decision as to the type of reconstruction was
based on surgeon preference, patient anatomy, and
comorbid conditions. Aortic-based reconstructions were
preferred, with extra-anatomic reconstructions primarily
reserved for patients considered at higher risk. Patients
who underwent surgery on an urgent basis or for emer-
gency problems that required concomitant renal artery
reconstructions were not included in this series.
Patients were followed up with postoperative renal
flow scans, duplex examination, and clinical and labora-
tory tests. Duplex examinations were performed at 3, 6,
and 12 months after surgery and yearly thereafter.
Postoperative renal dysfunction was defined as an increase
from baseline serum creatinine values in patients with cre-
atinine levels less than 1.1 mg/dL to greater than 1.4
mg/dL or more than a 10% change in a patient’s serum
creatinine level when baseline exceeded 1.5 mg/dL.
Patients who had symptomatic renovascular hypertension,
renal insufficiency, or abnormal results from a duplex
examination were evaluated with a further renal flow scan,
arteriography, or both. 
Duplex scans of renal artery reconstructions were per-
formed in all patients available for clinical follow-up and
formed the basis for graft patency determination. Duplex
examinations were performed with a high-resolution
Doppler ultrasound system (Siemens, Iselin, NJ) typically
with a 3.5-MHz transducer. Kidney length, rise or accel-
eration times, and resistive index were measured or calcu-
lated. Acceleration time was determined from the
following equation: (peak systolic velocity – end-diastolic
velocity)/peak systolic velocity. A resistive index less than
0.7 was accepted as normal. Acceleration time was deter-
mined from measuring time from onset of velocity accel-
eration to initial systolic peak. Acceleration times of more
than 100 ms were accepted as normal.18-20 Patency and
survival data were reported by means of life-table analysis.
SE was calculated at all intervals according to the stan-
dards of the Society for Vascular Surgery and the
International Society for Cardiovascular Surgery.21
RESULTS
Between March 1987 and December 1999, 458
patients underwent 538 renal artery bypass graft proce-
dures. Within this group, 414 patients underwent 489
renal bypass grafts with a prosthetic conduit. A total of 244
(59%) of these patients were male, 49 (12%) were diabetic,
and 147 (86%) were smokers. The mean age of this group
was 69 years (range, 10-92). The indications for surgery
included primary renovascular hypertension in 118 (24%),
renal insufficiency/ischemic nephropathy in 20 (4%),
pararenal aortic aneurysms involving the renal artery in 26
(5%), and RAS in association with either symptomatic aor-
toiliac occlusive or abdominal aortic aneurysm in 309
(63%) patients. Other indications included renal artery
aneurysm (8 patients), renal trauma (2 patients), infected
aortic graft (3 patients), mesenteric ischemia (1 patient),
pelvic kidney in association with other aortic disease (1
patient), and presence of accessory renal arteries in associ-
ation with severe aortic disease (1 patient). 
Operations were performed through a transperitoneal
approach in 11 patients (2%), through the left retroperi-
toneal approach in 424 (87%), and through a right
retroperitoneal approach in 54 (11%). Inflow choices
included aortic graft in 415 (85%), aorta in 47 (10%), iliac
artery in 19 (4%), hepatic artery in 4 (1%), and renal artery
in 3 (1%) procedures.
There were 23 surgical deaths within this group of
patients undergoing prosthetic renal artery bypass grafting
(5.5%). Causes of death included multisystem organ fail-
ure (12), cardiac arrest (5), colon ischemia (2), stroke (2),
renal failure (1), and bleeding (1). Nonfatal complications
occurred in 11.4% of patients and included multiple sys-
tem organ failure in 12 (2.4%), cardiac arrest in 10 (2%),
pulmonary in 6 (1.2%), stroke in 1 (0.2%), transient renal
failure in 15 (3.1%), mesenteric ischemia in 2 (0.4%),
wound infection in 3 (0.6%), and bleeding in 3 (0.6%).
There was a 1.4% early and 4.8% late occlusion rate. 
Renal function worsened in 15 patients. Baseline
serum creatinine values within this group were less than
1.5 mg/dL in two patients, greater than 1.5 but less than
2.0 mg/dL in 5 patients, greater than 2 but less than 3.0
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mg/dL in 2 patients, and greater than or equal to 3
mg/dL in 3 patients. The remaining patient was dialysis
dependent on admission. Within this group of patients,
two patients with preoperative serum creatinine values
over 3.0 mg/dL underwent dialysis. 
In patients who underwent revascularization either for
intractable hypertension or for renal salvage, 26%
improved, 68% stabilized, and 6% worsened. In patients
undergoing repair for asymptomatic renal lesions with
concomitant aortic replacement procedures, 84% (308/
367) were hypertensive according to their medical history
but had systolic pressures less than 160 mm Hg and dias-
tolic pressures less than 90 mm Hg on presentation. None
of those patients available for follow-up have had
intractable hypertension over the long term. Long-term
data about renal function were unavailable for most of 
the asymptomatic group. However, no patient with
asymptomatic renal stenosis had renal dysfunction requir-
ing dialysis.
Within the study group of 414 patients, 47 patients
underwent 60 primary renal artery reconstructions (Group
I) for predominantly symptomatic disease (renovascular
hypertension or renal salvage). The remaining 367 patients
underwent 429 adjunctive renal artery reconstructions
with aortic replacement procedures for aortic aneurysm or
aortoiliac disease (Group II). The mortality rates were
6.4% (3/47) in Group I and 5.4% (20/367) in Group II.
Nonfatal complications occurred after 27% (16/60) of
Group I and 9% (39/429) of Group II procedures.
Patency data of all prosthetic renal bypass grafts are
shown in Tables I and II and Fig 1. All bypass grafts
remained 100% patent at 30 days, 98% at 1 year, and 96%
at 5 years. One bypass graft occluded at 38 months post-
operatively and was successfully treated with surgical
thrombectomy.
Procedures performed were also subdivided according
to symptoms. (Patency data are shown in Tables IV-VIII,
online only.) A total of 309 patients underwent renal
artery reconstructions with prosthetic conduits for asymp-
tomatic disease (Table V, online only). Most (305/309) of
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these were performed as adjunctive procedures to aortic
replacement. A total of 118 procedures were performed
for primary renovascular hypertension of which 44 pri-
mary (Table VI, online only) and 74 adjunctive renal
artery reconstructions were performed (Table VII, online
only). Twenty patients underwent primary renal artery
reconstruction for renal salvage (Table VIII, online only).
Because the number of patients within this subset was
small, the SE exceeded 10% beyond 2 years. There were
no adjunctive aortic reconstructions in patients with pri-
mary renal salvage indications for operation. Secondary
patency rates of prosthetic renal artery bypass subdivided
according to symptoms are shown in Fig 2. 
Cumulative patient survival in all patients undergoing
renal artery reconstruction with prosthetic grafts is shown
in Fig 1 and Table III. Patient survival was 94% at 30 days,
88% at 1 year, 81% at 3 years, and 79% at 5 years. The
length of follow-up in this patient population was 24
months (range, 1-144 months). 
DISCUSSION
Renal artery reconstruction is currently an accepted
form of treatment for hypertension and renal insufficiency
resulting from severe stenotic disease of one or both renal
arteries. Riley et al22 showed cure or improvement in
blood pressure in more than 80% of patients after revascu-
larization for ischemic nephropathy. In addition, the effect
of operative treatment is maintained over a long-term 
follow-up with a lower risk of early death from cardiovas-
cular events in patients with a long-term hypertensive
response to renal revascularization.23
The performance of renal artery reconstruction in the
setting of asymptomatic stenosis has remained controver-
sial and is recommended by some only in the setting of a
good risk patient when aortic reconstruction is a primary
indication for operation.5 However, Chaikof et al6 have
shown that adjunctive repair of renal stenoses during aor-
tic surgery even in the absence of severe hypertension or
renal insufficiency may be accomplished safely and effec-
tively. Furthermore, concomitant repair is recommended if
Fig 1. Primary and secondary patency of all prosthetic renal
artery bypass grafts. Dashed lines indicate SE greater than 10%.
Fig 2. Patency of prosthetic renal artery bypass grafts subdivided
according to symptoms. Dashed lines indicate SE greater than 10%.
operative risk is acceptable and a reasonable life expectancy
can be anticipated. 
The aforementioned studies have drawn off natural his-
tory and long-term angiographic follow-up studies that
have shown rates of disease progression as high as 53% in
stenotic renal arteries that may be associated with decreases
in renal size and function.8-10 In the current study, patients
who did not have a serum creatinine level less than 1.5
mg/dL or severe intractable hypertension were considered
symptom free. However, more than 80% of the asympto-
matic group were hypertensive, according to their medical
history, and were taking at least one antihypertensive med-
ication. Thus, one may argue that most in the asymptomatic
group should be placed in the symptomatic category. In
Zierler et al’s9 study, more than 90% of patients were taking
at least one antihypertensive medication with only 6% being
normotensive at baseline evaluation. However, Tollefson et
al8 reported disease progression in 53% of stenotic renal
arteries in his population of whom 60% did not have or
were not treated for hypertension. Although long-term
progression of occlusive disease may occur in the absence of
hypertension, loss of renal function may not be clinically
detectable as demonstrated by elevation of serum creatinine
level and progression of hypertension in only 29% and 33%
of this patient population, respectively.
In the current study, repair of asymptomatic renal
lesions was safely accomplished because no patient in this
group had permanent renal dysfunction. This emphasizes
JOURNAL OF VASCULAR SURGERY
130 Paty et al July 2001
Table II. Secondary graft patency
Interval (mo) Grafts at risk Occlusions Interval patency Cumulative patency SE%
0-1 489 7 0.984 0.984 0.563
2-12 391 1 0.997 0.981 0.684
13-24 211 0 1.000 0.981 0.931
25-36 140 0 1.000 0.981 1.143
37-48 102 0 1.000 0.981 1.339
49-60 70 1 0.981 0.962 2.241
61-72 37 1 0.967 0.930 4.045
73-84 23 0 1.000 0.930 5.130
85-96 7 0 1.000 9.930 9.3
97-108 4 0 1.000 0.930 12.303
Table III. Patient survival
Interval (mo) Patients at risk Deaths Interval survival Cumulative survival
0-1 414 24 0.938 0.938
2-12 335 17 0.937 0.879
13-24 185 7 0.955 0.839
25-36 122 4 0.963 0.808
37-48 90 3 0.961 0.776
49-60 60 2 0.957 0.743
61-72 31 0 1.000 0.743
73-84 20 2 0.862 0.640
85-96 7 0 1.000 0.640
97-108 4 1 0.600 0.384
Table I. Primary graft patency
Interval (mo) Grafts at risk Occlusions Interval patency Cumulative patency SE%
0-1 489 7 0.984 0.984 0.563
2-12 391 1 0.997 0.981 0.684
13-24 211 0 1.00 0.981 0.931
25-36 140 0 1.00 0.981 1.143
37-48 102 1 0.988 0.969 1.689
49-60 69 1 0.981 0.950 2.557
61-72 37 1 0.967 0.919 4.300
73-84 23 0 1.00 0.919 5.454
85-96 7 0 1.00 0.919 9.886
97-108 4 0 1.00 0.919 13.078
a point also important in the treatment of asymptomatic
carotid stenosis in that repair with a minimum of compli-
cations related to surgical treatment is a requisite.24,25
Also in this study, concomitant renal reconstruction with
aortic replacement procedures had mortality rates compa-
rable with that of primary renal artery reconstructions
with prosthetic conduits. Thus, simultaneous aortic recon-
structions may not affect the outcome of renal artery
reconstructions with the caveat that the groups may not
necessarily be comparable because of differences in bypass
graft inflow and operative indications.
A more pertinent question is whether renal artery
reconstructions affect the outcome of aortic reconstruc-
tive procedures. During the 12-year period of study, aor-
tic replacement for abdominal aortic aneurysm alone had
a 5.7% mortality rate, which was similar to a 4.7% mortal-
ity rate for aortic replacement with adjunctive renal artery
bypass graft. However, in patients with aortoiliac occlusive
disease, the mortality rate of combined procedures was
8.3% versus 3.6% in aortic replacement for occlusive dis-
ease without renal reconstructions. These differences may
reflect a greater degree of systemic atherosclerosis in the
population of patients with aortoiliac occlusive disease in
conjunction with severe renal artery occlusive disease.
Thus, the vascular surgeon should take into consideration
that a high mortality rate in this population may occur
when embarking on adjunctive renal artery reconstruction
in the occlusive population. 
Because many authors still recommend autogenous
methods of renal revascularization, the purpose of the cur-
rent study was to evaluate the use of prosthetic conduits in
this setting. The use of prosthetic grafts for renal artery
bypass grafting remains controversial because there is a
prevailing belief that stenoses and eventual occlusions
occur in prosthetic bypass grafts more frequently than in
autogenous vein bypass grafts.14,15 In addition, there is
concern about possible graft infection and enteric interac-
tions in the setting of prosthetic bypass graft.13,16,17 This
has led several authors to recommend autogenous vein for
both primary aortorenal reconstructions and extra-
anatomic renal revascularizations.23,26,27 Although four
patients in the current study with either infected aortic
grafts (3) or mesenteric ischemia (1) underwent successful
renal artery bypass grafting with PTFE without adverse
long-term sequelae, we do not recommend routine use of
prosthetic conduits in these settings because of the poten-
tial long-term infectious complications.
During the same 12-year period reviewed in this study,
44 patients underwent 49 renal bypass grafts with autoge-
nous saphenous vein. Operative indications included reno-
vascular hypertension or renal insufficiency in 43 (88%),
renal stenosis associated with either symptomatic aortoil-
iac occlusive disease or abdominal aortic aneurysm in 4
(8%), and other indications in 2 (4%). Inflow sources for
bypass grafts included aortic graft in 2 (4%), aorta in 10
(20%), renal artery in 11 (22%), hepatic artery in 22
(45%), iliac artery in 3 (6%), and superior mesenteric
artery in 1 (2%). Graft patency was 90% at 30 days, 94% at
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1 year, and 88% at 3 years. Patient survival rate was 97% at
30 days, 1 year, and 3 years. Although the patency rates of
prosthetic bypass graft in the current study are comparable
with reconstructions with vein, the group demographics
are not. The indications for vein bypass graft were pre-
dominantly for symptomatic disease, and inflow sources
were iliac or visceral in most patients. 
In terms of renal artery bypass grafts as a reconstruc-
tive method, however, the use of vein as a conduit may be
fraught with several problems that may be peculiar to this
conduit. In particular, early occlusion may occur as a result
of the presence of a valve near the proximal anastomosis
with subsequent stagnation of flow under the valve cusp
and thrombosis.13 In addition, in long-term follow-up,
graft stenoses may develop in up to 41% of patients.28
Suture line stenoses may occur in up to 17% of cases.29
Aortorenal bypass grafts that use the saphenous vein may
also develop fibrotic stenosis at the site of venous valves
beyond the anastomosis.12 Additionally, in the pediatric
age group, aneurysmal formation may occur with primary
aortorenal bypass graft with saphenous vein, leading sev-
eral authors to recommend hypogastric artery as the pri-
mary conduit or saphenous vein reinforced with polyester
fiber (Dacron) when revascularization is performed in this
age group.1,12,30,31
Dean12 alluded to advantages of synthetic conduits for
renal bypass grafts. For example, a variety of graft sizes are
available, and a separate dissection field is not required.
Also, the attributes of short length and high flow rates
may render graft surface characteristics and thrombo-
genicity relatively unimportant and provide a high proba-
bility of long-term patency regardless of conduit type.
Other authors have used synthetic conduits with good
results. Cormier et al32 reported on a series of 74 renal
revascularizations performed over an 8-year period with
PTFE and found an 85% patency at 6 years.
In the current study we found that prosthetic conduits
have functioned well in the setting of renal artery bypass
graft with acceptable long-term patency rates. Although
no patients in the asymptomatic group had intractable
hypertension in follow-up, specific data about renal func-
tion were unavailable. A prospective long-term study may
better answer this question. Within the current study, the
prosthetic and autogenous vein groups cannot be directly
compared because of the differences in operative indica-
tions and inflow source. We have not found undue rates of
complications related to conduit type such as bleeding or
infection. With patency rates of 93% at 7 years, PTFE con-
duits in renal bypass grafts have an acceptable and durable
result whether used for primary arterial reconstruction or
for concomitant reconstruction with an aortic procedure.
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